NUWE — Nuwellis, Inc.

Nuwellis, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: $2.4 million, up 4% year-over-year and 9% sequentially.
• U.S. Console Sales: Increased by 208%, with eight units sold compared to three in the prior year.
• Gross Margin: Expanded to 68.2%, up from 58.4% year-over-year.
• Operating Expenses: $4.1 million for Q4, a $400,000 increase compared to the prior year.
• Full-Year Revenue: $8.3 million, a 5% decline from 2024.
• Full-Year Operating Loss: $17.5 million, including a $6.4 million noncash warrant valuation expense.
• Cash Position: Ended the year with approximately $1.2 million in cash and no debt.

2. Strategic Updates and Business Highlights:

• The company underwent significant structural changes in 2025, focusing on operational discipline and simplifying its business model.
• Transitioned manufacturing to KDI Precision Manufacturing to enhance reliability and scalability.
• Refined international strategy by exiting underperforming markets, particularly in the EU.
• Strengthened focus on the cardiorenal continuum, particularly in heart failure and pediatrics, with a notable 814% growth in these segments.
• Received a National Institutes of Health grant to support pediatric device development, enhancing intellectual property and clinical validation.

3. Forward Guidance and Outlook:

• Nuwellis aims to leverage its strategic clarity to achieve more predictable commercial performance in 2026.
• Plans to maintain financial rigor, focus on gross margin consistency, and prioritize capital efficiency.
• The company anticipates growth through increased utilization in existing accounts and the integration of the recently acquired Rendiatek technology.

4. Bad News, Challenges, or Points of Concern:

• Full-year revenue decline of 5% indicates ongoing challenges in consumables utilization and pricing pressures.
• Operating loss remains significant, raising concerns about long-term profitability.
• The decision to terminate the REVERSE-HF clinical trial reflects cash management challenges and the need to prioritize resources.
• The exit from the EU market highlights difficulties in international operations and market performance.

5. Notable Q&A Insights:

• The salesforce was reinforced to 24 individuals, with a focus on critical care and existing accounts for increased utilization.
• The acquisition of Rendiatek is expected to enhance capabilities in measuring renal output in critical care settings, aligning with the company’s strategic focus.
• Management emphasized the importance of operational stability and quality improvements following prior product recalls and quality issues.
• The company is committed to leveraging existing relationships in heart failure to expand into critical care markets.

Overall, Nuwellis, Inc. is positioning itself for a more focused and disciplined approach in 2026, with strategic initiatives aimed at enhancing operational performance and capitalizing on growth opportunities in the cardiorenal space, despite facing significant financial challenges and market pressures.